ArticleWorld journal of surgery2010
Causes and treatment of recurrent hyperparathyroidism after subtotal parathyroidectomy in the presence of multiple endocrine neoplasia 1.
Article in World journal of surgery, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 43 citations in OpenAlex.
- Recurrent Primary Hyperparathyroidism in Multiple Endocrine Neoplasia Type 1 Syndrome.Physiological research · 2023Article
- [The clinical practice guidelines for primary hyperparathyroidism, short version].Problemy endokrinologii · 2021Review
- Multiple endocrine neoplasia 1: a broad overview.Therapeutic advances in chronic disease · 2021Review
- Impact of "Tailored" Parathyroidectomy for Treatment of Primary Hyperparathyroidism in Patients with Multiple Endocrine Neoplasia Type 1.World journal of surgery · 2018Article
- When Parathyroidectomy Should Be Indicated or Postponed in Adolescents With MEN1-Related Primary Hyperparathyroidism.Frontiers in endocrinology · 2018Article
- Persistent and recurrent hyperparathyroidism.Updates in surgery · 2017Review
- MEN1, MEN4, and Carney Complex: Pathology and Molecular Genetics.Neuroendocrinology · 2016Review
- Hereditary hyperparathyroidism--a consensus report of the European Society of Endocrine Surgeons (ESES).Langenbeck's archives of surgery · 2015Review
- Reoperations for persistent or recurrent primary hyperparathyroidism: results of a retrospective cohort study at a tertiary referral center.Medical science monitor : international medical journal of experimental and clinical research · 2014Article
- Primary hyperparathyroidism in multiple endocrine neoplasia type 1: when to perform surgery?Clinics (Sao Paulo, Brazil) · 2012Review
- Total parathyroidectomy in a large cohort of cases with hyperparathyroidism associated with multiple endocrine neoplasia type 1: experience from a single academic center.Clinics (Sao Paulo, Brazil) · 2012Review
- Primary hyperparathyroidism in patients with multiple endocrine neoplasia type 1.International journal of endocrinology · 2010Article
Corrections and comments
- Erratum issuedFornos, Joan Sancho [corrected to Sancho Insenser, Joan]
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSubtotal parathyroidectomy (SPTX) is the treatment of choice for hyperparathyroidism in a patient with multiple endocrine neoplasia type 1 (HPT-MEN-1). There are scarce data on the causes, timing, and appropriate surgical treatment of patients with recurrent HPT-MEN-1. The aim of this study was to investigate the timing, causes, site of recurrence, and surgical treatment of recurrent HPT-MEN-1 in patients who underwent SPTX.
methodsThe study was a retrospective review of prospectively collected data on patients with HPT-MEN-1 with SPTX at two referral institutions. The data collected included the following: demographics, duration of follow-up, weight of resected parathyroid tissue, type of remnant, time to reoperation, cause/site of recurrence, and surgical treatment. We studied prognostic factors of recurrence.
resultsA total of 69 patients underwent SPTX and were followed for a mean of 75.3 months. After the surgery, 15 patients were left with a single "normal" gland and 54 with a 50- to 70-mg remnant of a partially excised abnormal gland. Nine patients (13%) had a recurrence within a mean of 85 months (12-144 months). Patients with a recurrence had been followed longer (115 vs. 66 months; p = 0.005). Five recurrences occurred in a parathyroid remnant, 3 in a previously "normal" gland; the fifth recurrence was in both a hyperplastic remnant and a fifth gland. Remedial surgery included five subtotal resections and four immediate parathyroid autotransplantations. Two patients had a second recurrence due to a supernumerary gland. Factors related with recurrence are the follow-up time (p < 0.01) and thymectomy (p < 0.003).
conclusionsRecurrence of HPTP-MEN-1 usually is located in preserved parathyroid tissue with no preference for a previously normal gland or a remnant. A second recurrence is most likely seen in a supernumerary gland. Recurrence is associated with the follow-up time and thymectomy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.